Benitec Biopharma (ASX:BLT) FCF Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 1997. Start your Free Trial

What is Benitec Biopharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Benitec Biopharma's Free Cash Flow for the three months ended in Mar. 2024 was A$-9.41 Mil. Benitec Biopharma's Revenue for the three months ended in Mar. 2024 was A$0.00 Mil. Therefore, Benitec Biopharma's FCF Margin % for the quarter that ended in Mar. 2024 was 0.00%.

As of today, Benitec Biopharma's current FCF Yield % is -20.60%.

The historical rank and industry rank for Benitec Biopharma's FCF Margin % or its related term are showing as below:

ASX:BLT' s FCF Margin % Range Over the Past 10 Years
Min: -306450 Med: -3516.28 Max: 37.97
Current: -306450

During the past 11 years, the highest FCF Margin % of Benitec Biopharma was 37.97%. The lowest was -306450.00%. And the median was -3516.28%.

ASX:BLT's FCF Margin % is ranked worse than
98.95% of 1046 companies
in the Biotechnology industry
Industry Median: -144.01 vs ASX:BLT: -306450.00

Benitec Biopharma FCF Margin % Historical Data

The historical data trend for Benitec Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Benitec Biopharma FCF Margin % Chart

Benitec Biopharma Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Margin %

Get a 7-Day Free Trial

37.97

-7,841.13

-22,172.73

-21,771.15

-23,963.39

Benitec Biopharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-7,450.62	-61,020.00	-	-	-

Competitive Comparison of Benitec Biopharma's FCF Margin %

For the Biotechnology subindustry, Benitec Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Benitec Biopharma's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Benitec Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Benitec Biopharma's FCF Margin % falls into.

Benitec Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Benitec Biopharma's FCF Margin for the fiscal year that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	-26.839	/	0.112
	=	-23,963.39 %

Benitec Biopharma's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-9.406	/	0
	=	%

Benitec Biopharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of Benitec Biopharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Benitec Biopharma (ASX:BLT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Benitec Biopharma Inc (ASX:BLT) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BNTC:USA

Address

3940 Trust Way, Hayward, CA, USA, 94545

Website

https://www.benitec.com

Benitec Biopharma Inc is a biotechnology company developing a proprietary therapeutic technology platform that combines RNA interference with gene therapy for providing sustained, long-lasting silencing of disease-causing genes from a single administration. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The company is developing product candidates in chronic and life-threatening human disease areas including Orphan disease: Oculopharyngeal Muscular Dystrophy (OPMD) and Infectious disease: Hepatitis B Virus (HBV). BB-301 is currently under development by the group; it is designed to slow, or halt, the disease progression.